Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Tolerability of Triplet Therapy in Multiple Myeloma

July 17th 2020

Therapy Initiation Prior to Cytogenetic Testing Results

July 17th 2020

Frontline Triplet Therapies in Multiple Myeloma

July 17th 2020

CAR T Pioneers Describe Challenges Faced in Cancer

July 16th 2020

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

Dr. Daver on the Advancing Treatment Landscape in AML

July 16th 2020

Naval G. Daver, MD, discusses the advancing treatment landscape in both acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. Daver on the Utility of Maintenance Therapy in AML

July 15th 2020

Naval G. Daver, MD, discusses the utility of maintenance chemotherapy in acute myeloid leukemia.

Closing Thoughts on Treatment of R/R DLBCL

July 15th 2020

Improving Outcomes in Patients With R/R DLBCL

July 15th 2020

Emerging Therapies for R/R DLBCL

July 15th 2020

Safety and Efficacy of Oral Agents in R/R DLBCL

July 15th 2020

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

July 15th 2020

CD19-Directed Therapies for Treatment of R/R DLBCL

July 15th 2020

CAR T in R/R DLBCL: Safety and Patient Selection

July 15th 2020

ASCO 2020 Data: CAR T in R/R DLBCL

July 15th 2020

Role of CAR T-cell Therapy in R/R DLBCL

July 15th 2020

Treatment in Transplant-ineligible R/R DLBCL

July 15th 2020

Prognosis of R/R DLBCL

July 15th 2020

Standard of Care for Treatment of DLBCL

July 15th 2020

Phase 3 Data With Eprenetapopt Plus Azacitidine Anticipated in High-Risk MDS/AML

July 14th 2020

David Sallman, MD, discusses the combination of eprenetapopt and azacitidine, a new standard of care for patients with myelodysplastic syndromes with a susceptible TP53 mutation.

Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia

July 14th 2020

Steven P. Treon, MD, PhD, discusses the role of BTK inhibitors in Waldenström macroglobulinemia.